Lonza to acquire Exosomics Service Unit in Siena, Italy to expand development service offering in exosome bioprocessing Expertise in exosomes isolation and characterization will drive innovation in this field Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition industries, announced today the acquisition of the service unit from Exosomics, a leading extracellular vesicles […]
Read MoreAutor: Firma Lonza Group Ltd.
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
Lonza to acquire and operate Codiak’s Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline Lonza and Codiak to establish a Center of Excellence focused on exosome manufacturing and characterization technologies Lonza to gain access to the worldwide, exclusive and sub-licensable rights of Codiak’s high-throughput exosome manufacturing technology Codiak to receive […]
Read MoreCapital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through Long-Term Growth
At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term investment program will drive sustainable business growth 2021 CAPEX anticipated at around 25% of sales, and remain elevated at current levels for the next few years, returning to high-teens by 2025 2024 […]
Read MoreLonza Invests to Expand Drug Product Development and Manufacturing Services in Switzerland
. Lonza will invest to expand its drug product manufacturing network in Switzerland The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel (CH) The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service […]
Read MoreTriumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
. Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon® platform at the C3i Center Inc (C3i) in Montreal Transitioning to Lonza’s Cocoon® Platform enabled Triumvira to escalate development efforts and achieve IND approval in less than a year The Phase 1/2 trial is actively enrolling HER2-overexpressing cancer patients at […]
Read MorePhilippe Deecke appointed as Chief Financial Officer of Lonza Group
Lonza appoints Philippe Deecke as CFO and member of the Lonza Group Executive Committee Philippe brings a wealth of experience from a 30-year career, which includes senior leadership roles in Novartis finance and time working as a McKinsey consultant He will commence his tenure with Lonza Group on 1 December 2021 Philippe succeeds Rodolfo […]
Read MoreLonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Sheba Medical Center at Tel Hashomer, […]
Read More
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including Moderna Divestment of Specialty Ingredients business completed on 1 July 2021 Path forward for a […]
Read MoreLonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of […]
Read MoreLonza Completes Divestment of Specialty Ingredients Business
. Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion. Albert M. Baehny, Chairman, Lonza commented: “Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new […]
Read More